The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-bydroxytryptamine(2A) receptor antagonist, in rats

British Journal of Pharmacology

Volumn 121, Issue 3, 1997, Pages 515-525

  Okuyama, Shigeru ^a   Chaki, Shigeyuki ^a   Kawashima, Naoya ^a   Suzuki, Yoshiko ^a   Ogawa, Shin Ichi ^a   Kumagai, Toshihito ^a   Nakazato, Atsuro ^a   Nagamine, Masashi ^b   Yamaguchi, Kazumasa ^c   Tomisawa, Kazuyuki ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

^b NIHON NOHYAKU CO LTD   (Japan)

^c Nihon Bioresearch Inc   (Japan)

Author keywords

5 hydroxytryptamine(2A); Antipsychotic activities; Apomorphine; Behavioural pharmacology; Clozapine; Dopamine D4 receptor antagonist; Electrophysiology; Haloperidol; Methamphetamine; NRA0045; Phencyclidine; Receptor antagonist

Indexed keywords

2 AMINO 4 (4 FLUOROPHENYL) 5 [1 [4 (4 FLUOROPHENYL) 4 OXOBUTYL] 3 PYRROLIDINYL]THIAZOLE; 2 AMINO 4 (4 FLUOROPHENYL) 5 [1 [4 (4 FLUOROPHENYL) 4 OXOBUTYL]PYRROLIDIN 3 YL]THIAZOLE; APOMORPHINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; METHAMPHETAMINE; NEUROLEPTIC AGENT; PHENCYCLIDINE; SEROTONIN 2A ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; EXTRAPYRAMIDAL SYNDROME; INTRAPERITONEAL DRUG ADMINISTRATION; LIMBIC SYSTEM; LOCOMOTION; MALE; MAZE TEST; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOSIS; RAT; SCHIZOPHRENIA; STEREOTYPY; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; CLOZAPINE; DOPAMINE ANTAGONISTS; MALE; MAZE LEARNING; METHAMPHETAMINE; MOTOR ACTIVITY; PYRROLIDINES; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D4; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; THIAZOLES;

EID: 8244242524     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701164     Document Type: Article

References (57)

1. 1 adrenoceptor antagonists. Conformationally flexible analogues of the atypical antipsychotic sertindole. J. Med. Chem., 39, 3723-3738.
2. ALDESSARINI, R.J. & TARSEY, D. (1980). Dopamine and the pathophysiology of dyskinesias induced by antipsychotic compounds. Ann. Rev. Neurosci., 3, 23.
3. 2 receptor blocking agent. Curr. Ther. Res., 40, 492-499.
4. 2 receptor mRNA. Brain Res., 564, 203-219.
5. BOYER, P., LECRUBIER, Y. & PUECH, A.J. (1990). Treatment of positive and negative symptoms: pharmacological approaches. Mod. Proc. Pharmacopsychiatry, 24, 152-174.
6. 4 antagonists. J. Med. Chem., 39, 1946-1948.
7. BUNNEY, B.S. (1977). Central dopaminergic system: two in vivo electrophysiological models for predicting therapeutic efficacy and neurological side effects of putative antipsychotic compounds. In Animal Models in Psychiatry and Neurology, ed. Hanin, I & Usdin, E. pp. 91-104, New York: Pergamon Press.
8. BUNNEY, B.S., WALTERS, J.R., ROTH, R.H. & AGHAJANIAN, G.K. (1973). Dopaminergic neurones: effects of antipsychotic compounds and amphetamine on single cell activity. J. Pharmacol. Exp. Ther., 185, 560-571.
9. CASEY, D.E. (1989). Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology, 99, S47-S53.
10. CHIODO, L.A. & BUNNEY, B.S. (1983). Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurones. Neuroscience, 3, 1607-1619.
11. CHOUINARD, G., JONES, B., REMINGTON, G., BLOOM, D., ADDINGTON, D., MACEWAN, G.W., LABELLE, A., BEAUCLAIR, L. & ARNOTT, W. (1993). A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol., 13, 24-40.
12. EVENDEN, J.L. & RYAN, C.N. (1990). Behavioural responses to psychomotor stimulant compounds: localization in the central nervous system. In Psychotropic Compounds of Abuse, ed. Balfour, D.J.K. pp. 1-21, New York: Pergamon Press.
13. GEYER, M.A. & BRAFF, D.L. (1990). Dopaminergic effects of LSD in an animal model of sensorimotor-gating deficits in schizophrenia. Biol. Psychiatry, 27, 97A.
14. GEYER, M.A., SWERDLOW, N.R., MANSBACH, R.S. & BRAFF, D.L. (1990). Startle response models of sensorimotor gating and habituation deficits in schizophrenia. Brain Res. Bull., 25, 485-498.
15. 2 dopamine receptor isoforms. Nature, 342, 923-936.
16. GOLDSTEIN, J.M., LITWIN, L.C., SUTTON, E.B. & MALICK, J.B. (1993). Seroquel: electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology, 112, 293-298.
17. 4 receptors. Br. J. Pharmacol., 117, 1625-1632.
18. HIRSCHOWITZ, J., HITZEMANN, R., BURR, G. & MAURSET, A. (1991). A new approach to dose reduction in chronic schizophrenia. Neuropsychopharmacology, 5, 103-113.
19. HOFFMAN, D.C. & DONOVAN, H. (1995). Catalepsy as a rodent model for detecting antipsychotic compounds with extrapyramidal side effect liability. Psychopharmacology, 120, 128-133.
20. JAVITT, D.C. & ZUKIN, S.R. (1991). Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry, 148, 1301-1308.
21. 2A antagonist with a favorable CNS Safety profile. J. Pharmacol. Exp. Ther., 277, 968-981.
22. KEHNE, J.H., SANT, W.W. & SORENSON, C.A. (1981). The effects of radio-frequency lesions of the nucleus accumbens on D-amphetamine-induced locomotor and rearing behaviour in rats. Psychopharmacology, 75, 363-367.
23. KEHNE, J.H., PADICH, R.A., MCCLOSKEY, T.C., TAYLOR, V.L. & SCHMIDT, C.J. (1996b). 5-HT modulation of auditory and visual sensorimotor gating: I. Effects of 5-HT releasers on sound and light prepulse inhibition in Wistar rats. Psychopharmacology, 124, 95-106.
24. 4 receptor. J. Med. Chem., 39, 1941-1942.
25. 2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications. Eur. J. Pharmacol., 236, 483-486.
26. 4 receptor. Eur. J. Pharmacol., 273, R1-R3.
27. LEVINSON, D.F. (1991). Pharmacologic treatment of schizophrenia. Clin. Ther., 13, 326-352.
28. 2 antagonist. Mol. Pharmacol., 27, 600-611.
29. OGAWA, S., OKUYAMA, S., ARAKI, H., NAKAZATO, A. & OTOMO, S. (1994a). A rat model of phencyclidine psychosis. Life Sci., 55, 1605-1610.
30. OGAWA, S., OKUYAMA, S., ARAKI, H. & OTOMO, S. (1994b). Effect of NE-100, a novel sigma receptor ligand, on phencyclidine-induced cognitive dysfunction. Eur. J. Pharmacol., 263, 9-15.
31. 4 receptor antagonists: synthesis and structure-activity relationships of (S)-(+)-N-(1-benzyl-3-pyrrolidinyl)-5-chloro-4-[(cyclopropylcarbonyl)amine]-2- methoxybenzamide (YM-43611) and related compounds. J. Med. Chem., 39, 2764-2772.
32. 4 receptor antagonists: receptor-binding and neuropharmacological profiles. Soc. Neurosci. Abs., 22, 1771.
33. OKUYAMA, S., OGAWA, S., NAKAZATO, A. & OTOMO, S. (1995). Effect of NE-100, a novel sigma ligand, on phencyclidine-induced delayed cognitive function in rats. Neurosci. Letts., 189, 60-62.
34. OKUYAMA, S., SHIMAMURA, H., HASHIMOTO, S. & AIHARA, H. (1986). Electrophysiological and behavioural assessments of dopamine autoreceptor activation to apomorphine in rats. Arch. Int. Pharmacodyn. Ther., 284, 246-254.
35. 4 receptor: sequence, gene structure, and demonstration of expression in the cardiovascular system. New Biol., 4, 137-145.
36. PADICH, R.A., MCCLOSKEY, T.C. & KEHNE, J.H. (1996). 5-HT modulation of auditory and visual sensorimotor gating: II. Effects of 5-HT2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats. Psychopharmacology, 124, 107-116.
37. PAXINOS, G. & WATSON, C. (1986). The Rat Brain in Stereotaxic Coordinates (2nd ed). Australia: Academic Press.
38. REYNOLDS, G.P. (1992). Developments in the compound treatment of schizophrenia. Trends. Pharmacol. Sci., 13, 116-121.
39. 2 receptor blocker. Drug Dev. Res., 8, 205-211.
40. 4 receptors. J. Med. Chem., 39, 1943-1945.
41. SANCHEZ, C., ARNT, J., DRAGSTED, N., HYTTEL, J., LEMBOL, H.L., MEIER, E., PERREGAARD, J. & SKARSFELDT, T. (1991). Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug. Dev. Res., 22, 239-250.
42. 2A receptors in antipsychotic activity. Life Sci., 56, 2209-2222.
43. 2 receptors, clozapine occupies D4. Neuropsychopharmacology, 7, 261-284.
44. SEEMAN, P. (1995). Dopamine receptors: clinical correlates. In Psychopharmacology: The Fourth Generation of Progress, ed. Bloom, F.E. & Kupfer, D.V. pp. 295-302. New York: Raven Press.
45. SEEMAN, P. & VAN TOL, H.H.M. (1994). Dopamine receptor pharmacology. Trends Pharmacol. Sci., 15, 264-270.
46. SNYDER, S.H. (1981). Dopamine receptors, neuroleptics and schizophrenia. Am. J. Psychiatry, 138, 461-468.
47. STOCKTON, M.E. & RASMUSSEN, K. (1996). Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells. Psychopharmacology, 124, 50-56.
48. SWERDLOW, N.R., KEITH, V.A., BRAFF, D.L. & GEYER, M.A. (1991). Effects of spiperone, raclopride SCH 23390 and clozapine on apomorphine inhibition of sensorimotor gating of the startle response in the rat. J. Pharmacol. Exp. Ther., 256, 530-536.
49. SWERDLOW, N.R., BRAFF, D.L., TAAID, N. & GEYER, M.A. (1994). Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch. Gen. Psychiatry, 51, 139-154.
50. TAMMINGA, C.A., THAKER, G.K., BUCHANAN, R., KIRKPATRICK, B., ALPHS, D.L., CHASE, T.N. & CARPENTER, W.T. (1992). Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alteration with deficit syndrome. Arch. Gen. Psychiatry, 49, 522-530.
51. 4 antagonist. J. Med. Chem., 39, 2434-2437.
52. VAN TOL, H.H.M., BUNZOW, J.R., GUAN, H.-C., SUNAHARA, R.K., SEEMAN, P., NIZNIK, H.B. & CIVELLI, O. (1991). Cloning of the gene for a human dopamine D4 receptor with high affinity for antipsychotic clozapine. Nature, 350, 610-614.
53. WAGSTAFF, A.J. & BRYSON, H.M. (1995). Clozapine: A review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs, 4, 370-400.
54. WATANABE, H., NAKANO, S. & OGAWA, N. (1981). Pharmacokinetic study of apomorphine-induced stereotypy in food deprived rats. Pharmacol. Biochem. Behav., 14, 493-496.
55. WEIDEN, P., AQUILA, R. & STANDARD, J. (1996). Atypical antipsychotic drugs and long-term outcome in schizophrenia. J. Clin. Psychiatry, 57, Suppl. 53-60.
56. WEINBERGER, D.R. (1988). Schizophrenia and the frontal lobe. Trends Neurosci., 11, 367-370.
57. WHITE, F.J. & WANG, R.Y. (1983). Differential effects of classical and atypical antipsychotic compounds on A9 and A10 dopamine neurones. Science, 221, 1054-1057.